BiotechTube

Mavacamten

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypertrophic Cardiomyopathy

Conditions

Hypertrophic Cardiomyopathy

Trial Timeline

Oct 31, 2021 → Feb 28, 2022

NCT ID
NCT05135871

About Mavacamten

Mavacamten is a phase 1 stage product being developed by LianBio for Hypertrophic Cardiomyopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT05135871. Target conditions include Hypertrophic Cardiomyopathy.

What happened to similar drugs?

3 of 13 similar drugs in Hypertrophic Cardiomyopathy were approved

Approved (3) Terminated (0) Active (10)
✅RanolazineGilead SciencesApproved
✅MavacamtenBristol Myers SquibbApproved
✅MavacamtenBristol Myers SquibbApproved
🔄Mavacamten + PlaceboLianBioPhase 3
🔄Mavacamten + PlaceboBristol Myers SquibbPhase 3
🔄Mavacamten + PlaceboBristol Myers SquibbPhase 3
🔄MavacamtenBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05135871Phase 1Completed

Competing Products

20 competing products in Hypertrophic Cardiomyopathy

See all competitors
ProductCompanyStageHype Score
Mavacamten + PlaceboLianBioPhase 3
30
CT-G20 + PlaceboCelltrionPhase 1
21
candesartanAstraZenecaPhase 2
31
LCZ696 + PlaceboNovartisPhase 2
35
Eleclazine + PlaceboGilead SciencesPhase 2/3
30
RanolazineGilead SciencesApproved
43
PF-06473871 + PF-06473871PfizerPhase 2
27
PF-06473871 + PF-06473871PfizerPhase 2
35
EXC 001 + EXC 001 + EXC 001 + EXC 001PfizerPhase 2
35
MavacamtenBristol Myers SquibbApproved
50
Mavacamten + PlaceboBristol Myers SquibbPhase 3
44
MavacamtenBristol Myers SquibbPre-clinical
30
MavacamtenBristol Myers SquibbPre-clinical
33
MavacamtenBristol Myers SquibbApproved
47
MYK-224Bristol Myers SquibbPhase 2
27
mavacamtenBristol Myers SquibbPhase 2/3
38
mavacamtenBristol Myers SquibbPhase 2
35
MavacamtenBristol Myers SquibbPre-clinical
33
MavacamtenBristol Myers SquibbPre-clinical
30
Mavacamten + PlaceboBristol Myers SquibbPhase 3
40